We Invest, Develop and Orchestrate Your MedTech Commercialization in China
We Invest, Develop and Orchestrate Your MedTech Commercialization in China
Commercialize Your MedTech Products and Services with Established Registration, Manufacturing, Demand Generation, Marketing and Distribution Partners
End-to-End Execution from Your Innovation to Your First Revenues in RMB
Global MedTech innovations continue to surge with record levels of R&D across all geographies. As a result, record numbers of MedTech patents have been issued within the US, Europe and Japan. However, as companies commercialize these innovations, they are often faced with significant challenges when attempting to enter China, the second largest MedTech market in the world by revenue size.

Constellation Life Sciences (“CLS”), with our established, in-country management team and network of partners, is your ideal China commercialization arm. We will invest, navigate through the evolving regulatory landscape, develop a commercialization path, protect your intellectual property, manage your go-to-market and maximize your China revenues.

Historically, multinationals have done well importing high-end MedTech products and local companies have played in the lower-valued consumables and “me-too” segments. However, recent policy changes are pushing both multinational companies and local players into a new China MedTech segment – Local Premium. But, the path to “Local Premium” is challenge to both MNCs and local players, requiring new partnership models.
There are significant obstacles to navigate for both in-China large MNCs and those looking to enter China. Success means willingness to consider more creative paths and partnerships.
  • Fragmented & regional distribution
    There are 15,000 MedTech companies and 185,000 distributors in China - top 20 manufacturers make up just 14% of the market. Access is complex and convoluted, often times with zero visibility to end consumers.
  • Importing vs. localizing (OEM)
    China wants to increase the use of domestically produced devices in hospitals to 70% by 2025, making imported products less desirable. Imports also face significantly longer registration periods, higher taxes, and use limitations.
  • Selecting channel partnerships
    As China pushes patient flow to lower tier hospitals where foreign companies typically do not reach, companies will need to rethink GTM models and partner with those having large footprints in lower tier hospitals.
  • Significant resources & bandwidth
    Some registrations alone can take up to 3 years and millions of dollars. Commercializing, managing sales & marketing and gaining acceptance in reimbursement programs are extremely costly and cumbersome.